ApoB-48 and apoB-100 differentially influence the expression of type-III hyperlipoproteinemia in APOE*2 mice by Hinsdale, Myron E. et al.
 
Copyright © 2002 by Lipid Research, Inc.
 




This article is available online at http://www.jlr.org
 
ApoB-48 and apoB-100 differentially influence the 















 and Nobuyo Maeda
 
Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill,
Chapel Hill, NC 27599-7525
 
Abstract Apolipoprotein E (apoE) is essential for the









homozygotes exhibit type-III hyperlipoproteinemia (THL),
while the remaining homozygotes have less than normal















 mice) are markedly hyper-
lipoproteinemic, suggesting a species difference in lipid
metabolism (e.g., editing of apolipoprotein B) enhances
THL development. Since apoB-100 has an LDLR binding















































 mice have a significant reduction in IDL/LDL






























 mice. In vitro tests show the apoB-
100-containing VLDL are poorer substrates for lipoprotein
lipase than apoB-48-containing VLDL.  Thus, despite a
lowering in IDL/LDL-C, substituting apoB-48 lipoproteins
with apoB-100 lipoproteins did not improve the THL phe-
















 mice, because apoB-48 and
apoB-100 differentially influence the catabolism of lipopro-
teins.
 
—Hinsdale, M. E., P. M. Sullivan, H. Mezdour, and N.
Maeda.
 
 ApoB-48 and apoB-100 differentially influence the
expression of type-III hyperlipoproteinemia in APOE*2
mice. 
 
























Apolipoprotein E (apoE) is essential for the clearance
of chylomicron and VLDL remnants from the plasma.
Variant apoE proteins in humans are known to cause pri-
mary dysbetalipoproteinemia [or type-III hyperlipopro-
teinemia (THL)], which is characterized by the accumula-
 
tion of chylomicron and VLDL remnants in the plasma
and a high incidence of coronary artery and peripheral
vessel atherosclerosis (1). The most common form of
THL is associated with homozygosity for the APOE*2 al-





to the low density lipoprotein receptor (LDLR) in vitro.
However, the majority of APOE*2 homozygotes typically
have normal to below normal plasma levels of cholesterol
and triglycerides (TG) and only 5–10% of the homozy-
gotes develop THL. Thus, reductions in lipoprotein clear-
ance due to hormonal, dietary, and genetic changes re-
sulting in reduced LDLR function or capacity are thought
to trigger the THL (2). In support of this hypothesis,
some of these THL patients have other disorders such as
hyperuricemia, glucose intolerance, obesity, and hypothy-
roidism (3, 4). Nevertheless, the basic mechanism why
only 5–10% of APOE*2 homozygotes develop THL while
the remaining homozygotes have below normal choles-
terol levels remains unexplained.







 mice) which solely express the
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gardless of age and gender, exhibit many characteristics of




























 gene; FC, free cholesterol; FPLC, fast protein liquid chro-
matography; LDLR, low density lipoprotein receptor; LpL, lipoprotein
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profile (6). Dissecting the basis for the complete pene-






 mice would likely
contribute to a better understanding of the mechanism of
THL in humans. For example, decreased binding of the












 mice is likely one component of the THL phenotype
because a modest increase in expression of the LDLR can







At present, it is unknown what influence, if any, the dif-
ferent structural protein components of the remnant li-
poprotein particles have in THL. In humans, each chylo-
micron contains a single apoB-48, and each VLDL contains
a single apoB-100. The transcripts for the apoB-48 are




 transcripts, which intro-
duces a translational stop codon at 48% of the full length
coding sequence, as compared with the unedited tran-
scripts which generate apoB-100 (8, 9). Unlike apoB-100,
apoB-48 lacks LDLR binding domains, and consequently
apoB-48-containing lipoproteins are totally dependent on
apoE for clearance. Mice differ from humans, and pro-
duce apoB-48-containing particles from both the liver
and intestine, and approximately 20–30% of apoB-con-
taining particles in fasting mouse plasma contain apoB-48
(10, 11). The levels of apoB-48 containing particles pro-
duced by the liver, in the fed state, are speculated to be




 mRNA editing (11).
Since apoB-48 is dependent on apoE for clearance, the
higher amount of apoB-48-containing lipoproteins in







In this paper, we hypothesized that the hyperlipidemic






 mice would be improved if all






 mice had apoB-100







 mice that are deficient in apoB-100






Mice used in this study were generated from crosses of

















 kindly provided by Dr. Edward Rubin, Lawrence






















) used in experiments were










































 mice. They had mixed genetic background
between C57BL/6 and 129. The mice were maintained on PRO-
LAB ISOPRO RMH 3000 diet. All procedures were approved by
the University of North Carolina at Chapel Hill Institutional Ani-
mal Care and Use Committee. Mice were genotyped using PCR.















































350 bp fragment diagnos-


















































































) and intron 6 primers amplified the wild-








After a 5 h fast, the mice were anesthetized with avertin, and
blood was collected from the retroorbital sinus into microcentri-
fuge tubes containing 0.007 TIU aprotinin (Sigma), 0.19 mg








l of blood. Plasma total
cholesterol (TC) was determined using a diagnostic kit (Wako
Chemicals Inc.) as per kit instructions. For TG measurements, a
Sigma diagnostic kit was used as per kit instructions. HDL cho-
lesterol (HDL-C) was determined as previously described (13).
ApoE was measured using an ELISA with antibodies specific for
human apoE as described (14). For gel filtration analysis with





plasma from the indicated mice was fractionated using a Super-
ose 6 HR1/30 column (Pharmacia Biotech Inc.). For each 0.5
ml fraction collected, TC, TG, and apoE concentrations were
determined.
 
Agarose gels, SDS-PAGE, and Western blot analyses
 
Fasted plasma lipoproteins were fractionated by ultracentrifu-





C in a Beckman Optima TLX for each fraction. Fractions




 1.006, 1.02, 1.04, 1.06, 1.08, 1.10, and 1.21
g/ml. Fractions were dialyzed in 50 mM Tris, 1 mM EDTA, and




C, and plasma equivalents were loaded on pre-
cast 4–15% acrylamide gels (BioRad) or precast 1% agarose gels
(Helena Laboratories). Molecular weight standards (BioRad)
were used to determine size of detected proteins. Stained gels
were scanned and analyzed with NIH Image software version
1.62. Western blots were probed with a rabbit polyclonal
(1:10,000) anti-mouse apoB antibody (a kind gift from Dr.
Harshini DeSilva) followed by a conjugated goat anti-rabbit anti-
body (1:40,000) (Calbiochem). Chemiluminescence (Amer-
sham Pharmacia Biotech) was used for detection of all second-





The ability of VLDL to act as a substrate for lipoprotein lipase
(LpL) was measured according to van Dijik et al. (15) with some
modifications. Plasma VLDL from individual animals was iso-




 1.006 g/ml and dialyzed.





taining 2, 4, 8, and 16 
 
g of VLDL-TG. These were incubated at
37C for 10 min. Reaction buffer was 0.1 M Tris pH 8.5 plus 1.0%
fatty acid free BSA. One hundred and fifty milliunits of bovine
milk LpL (Sigma-Aldrich, diluted to 15 U/ml with 0.1 Tris, 20%
glycerol v/v, pH 8.5) was added and the samples were incubated
for another 10 min. The reactions were terminated by adding 50
l of stop solution (50 mM KH2PO4, 0.1% v/v Triton X-100, ph
6.9) and placed on ice. Free fatty acids (FFA) were measured
using the non-esterified free fatty acid kit (NEFA C, Wako Chem-
icals). Duplicate samples, without LpL, were incubated to deter-
mine background FFA release. The FFA concentration for each
sample was plotted followed by curve fitting to a rectangular hy-
perbola using Dataraid software (written by Dr. Jolyon Jesty at
the State University of New York at Stony Brook). For 8.0 g of
TG substrate, released FFA per min per unit of enzyme was cal-
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culated and then analyzed byStudent’s t-test (JMP Statistical soft-
ware version 4.0.3, SAS Institute Inc.).
VLDL compositional analysis
The VLDL used in the lipase assay was analyzed for phospho-
lipid (PL), free cholesterol (FC), TC, and TG using commer-
cial kits from Wako Chemicals (PL, FC, and TC) and Sigma-
Aldrich (TG) as per kit instructions. Total protein was measured
using the Bradford assay (Pierce). Cholesterol ester (CE) mass
was estimated by multiplying the difference between FC and TC
by a factor of 1.67 (16). Percentages of TG, FC, PL, CE, and
protein in the total mass were then calculated. Two-tailed Stu-
dent’s t-test and linear correlation were used to analyze statisti-
cal significance.
Triglyceride secretion assay
The liver secretion of TG was assayed as described (17). Briefly, a
10% solution of Triton WR-1339 (Tyloxapol, Sigma-Aldrich) in
0.9% saline was injected into the tail vein at a dose of 0.7 mg/g body
weight (total volume injected was 200 l). Approximately 75 l of
blood was collected at time 0 (i.e., before Tyloxapol injection), 30
min. (i.e., after tyloxapol injection), 60 min, 120 min, and 180 min
using non-heparinized capillary tubes and was immediately added
to microcentrifuge tubes containing aprotinin (Sigma-Aldrich),
EDTA, and gentamicin. Plasma TG concentrations (mg/dl) were
then measured and normalized for liver weight. The mols TG se-
creted were then estimated for average total body plasma volume
(4.5% of body weight) as previously reported in the mouse (18).
These TG values (mols/g liver weight) were then plotted against
time for each mouse, and a linear curve fit was performed. The
slopes from the curve fit equations were used to calculate the mols
of TG secreted per gram of liver per hour and analyzed by t-test.
RESULTS
Plasma lipids
Plasma lipid and lipoprotein profiles in the Apoe2/2·
Apobec/ mice were significantly different from those in the
Apoe2/2 mice. Both females and males had significantly in-
creased plasma TG (60% and 100%, respectively) (Table
1). In addition, the females had an 18% decrease in TC
(P  0.03, student’s t-test) while the males had an 60%
increase in HDL-C concentrations (P  0.01, student’s
t-test)(Table 1). FPLC fractionation of the plasma followed
by lipid analysis of each fraction showed the increase in TG
of the Apoe2/2·Apobec/ mice was localized to the VLDL
fractions and the decrease in TC in the females was local-
ized to the LDL fractions (Fig. 1, left panel). A slight de-
crease in LDL-C was also seen in males (Fig. 1, right panel).
ApoE concentration and distribution
Plasma apoE-2 concentrations were similar between the
Apoe2/2·Apobec/ and Apoe2/2 mice (Table 1). However,
apoE-2 distribution in FPLC fractions was very different in
the Apoe2/2·Apobec/ mice having a reduction of 50–
60%, particularly in the IDL/LDL fractions (Fig. 1). This
apoE-2 distribution parallels the cholesterol reduction as
seen in the same FPLC fractions. These findings suggest
the Apoe2/2·Apobec/ mice have markedly less apoE bound
to lipoproteins (50% and 30% less in females and
males, respectively). In the males, but not in the females,
apoE-2 was reduced slightly in the HDL fractions. In both
male and female Apoe2/2·Apobec/ mice, the amount of
apoE-2 associated with the VLDL fraction was similar to
that in the Apoe2/2 mice despite the larger difference in
VLDL-TG.
Characteristics of lipoproteins fractionated
by ultracentrifugation
To further investigate the apolipoprotein content of
plasma lipoproteins in the females, plasma from 10 mice
of each genotype was pooled and fractionated by ultracen-
trifugation. Plasma equivalents of these fractions were sep-
arated by SDS polyacrylamide gel electrophoresis (Fig. 2A,
B). The Apoe2/2·Apobec/ plasma had less apoE-2 in the
1.02–1.04 fractions (Fig. 2A, right), as compared with the
Apoe2/2 plasma where apoE-2 was more evenly present in
fractions 1.006–1.04 (Fig. 2A, left). ApoA-I was primarily
associated with fractions 1.08–1.21 g/ml in the Apoe2/2·
Apobec/ mice as compared with the Apoe2/2 mice that had
a wider distribution of apoA-I, including the 1.04 and 1.06
fractions. Gels with reduced sample volume show (Fig.
2B) about a 1:2 ratio of apoB-100:B48 in the Apoe2/2 VLDL
while no apoB-48 was detectable in the Apoe2/2·Apobec/
VLDL. We estimated, by scanning densitometry of the
coomassie stained SDS-PAGE gel, the total amount of
apoB (apoB-48 plus apoB-100) in the Apoe2/2·Apobec/
plasma VLDL was twice that in the Apoe2/2 plasma VLDL.
This increase in VLDL apoB was also seen in males (data
not shown). In addition, the Apoe2/2·Apobec/ plasma had
18% more apoE in the 1.006 fraction but 26% less in
the 1.02 fraction than the same fractions from Apoe2/2
plasma. Therefore, in Apoe2/2·Apobec/ plasma, VLDL are
doubled, and the distribution of apoE and apoA-I is re-
stricted to the VLDL fractions and HDL fractions, respec-
tively.
When these ultracentrifugation fractions were sepa-
rated on agarose gels and stained with fat red 7B, we
found increased staining in the 1.006 fraction and less in
the 1.02 and 1.04 fractions in the Apoe2/2·Apobec/ mice
as compared with the Apoe2/2 mice (Fig. 2C, top). These
findings confirm the FPLC distribution of high VLDL-TG
levels in the Apoe2/2·Apobec/ plasma. Immunoblots of the
TABLE 1. Plasma lipids and apoE concentration
Gender Genotype TC TG HDL-C ApoE
mg/dl
Females Apoe2/2 (n  14) 347 	 71 165 	 65 49 	 10 33 	 8
Apoe2/2·Apobec/
(n  11) 285 	 39a 263 	 48b 53 	 14 36 	 8
Males Apoe2/2 (n  6) 290 	 40 159 	 44 48 	 22 28 	 9
Apoe2/2·Apobec/
(n  8) 281 	 47 325 	 56c 77 	 13d 34 	 7
Data are means 	 SD in mg/dl in plasma from mice fed normal
chow diet with 5.0% fat. TC, total cholesterol; TG, triglyceride; HDL-C,
HDL cholesterol.
a P  0.03, compared to Apoe2/2 females.
b P  0.001, compared to Apoe2/2 females.
c P  0.001, compared to Apoe2/2 males.
d P  0.01, compared to Apoe2/2 males.
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ultracentrifugation fractions using a polyclonal apoB anti-
body showed an 60% decrease in apoB containing lipo-
proteins in the 1.06 and their absence in 1.08 fractions
(Fig. 2C, bottom). Again, these findings were consistent
with the FPLC analyses that showed low IDL/LDL-C levels
in the Apoe2/2·Apobec/ mice. Phospholipid levels mea-
surements of the ultracentrifugation fractions showed an
25% increased in VLDL-PL and an 50–70% decreased
in LDL-PL (fractions 1.04–1.06) in the Apoe2/2·Apobec/
compared with those in the Apoe2/2 (Fig. 2D). In summary,
the Apoe2/2·Apobec/ mice have reduced IDL/LDL parti-
cles and increased VLDL particles as compared with the
Apoe2/2 mice.
Triglyceride secretion
An increase in TG particle secretion could increase
steady state levels of plasma TG in the Apoe2/2·Apobec/
mice. To test this possibility, we injected the Apoe2/2·
Apobec/ and Apoe2/2 mice with Triton WR-1339 and mea-
sured the accumulation of plasma TG over time. As shown
in Fig. 3, there was no significant difference in TG secre-
tion rates between the Apoe2/2·Apobec/and Apoe2/2 mice.
Therefore, the difference in plasma TG is not due to dif-
ferences in secretion rates of VLDL.
VLDL composition
The proportional masses of CE, FC, PL, TG, and pro-
tein in the Apoe2/2·Apobec/ VLDL (n  5) and the Apoe2/2
VLDL (n  5) (Fig. 4) showed that the Apoe2/2· Apobec/
VLDL, as compared with Apoe2/2, have significantly high
TG (47.6 	 1.6% vs. 37.4 	 2.8%, P  0.01) and low ester-
ified cholesterol (18.0 	 1.4% vs. 25.3 	 2.4%, P  0.03).
The percent of core lipids (TG plus CE mass) were, how-
ever, about equal. On an individual animal basis, CE con-
tent and TG content were inversely correlated each other
(r  0.99). Protein content was not different (10.6 	
0.3% vs. 10.3 	 0.1%, P  0.4). Because VLDL-CE in the
Apoe2/2·Apobec/ mice is 30% lower than that in the
Apoe2/2 mice (Fig. 4), the Apoe2/2·Apobec/ VLDL could be
up to 30% larger in size, or 30% more in number, or a
combination of both. However, since VLDL apoB levels
are higher in the Apoe2/2·Apobec/ mice, as judged from
PAGE gels (Fig. 2), the actual number of VLDL particles
in these mice is likely increased. Thus, these data suggest
Fig. 1. Fast protein liquid chromatography
(FPLC) fractionation of plasma. Total cholesterol
(TC), triglyceride (TG), and apoE-2 were measured
in each fraction. Fractions containing VLDL, IDL,
LDL, and HDL are indicated.
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Fig. 2. Analyses of ultracentrifugation fractions of plasma from Apoe2/2 and Apoe2/2·Apobec/ female mice. A: SDS polyacrylamide gel (4–
15%) analysis using fractions from the Apoe2/2 mice (left) and fractions from Apoe2/2·Apobec/ mice (right). ApoB-100 (B100), apoB-48
(B48), apoE-2 (E2), and apoA-I (A1) are indicated. B: Apoe2/2and Apoe2/2·Apobec/ fractions 1.006 and 1.02 loaded with half the amounts of
gels in A. C (top): Agarose gel electrophoresis of fractions from Apoe2/2 (left) and Apoe2/2·Apobec/ (right) and stained with fat red 7B. (bot-
tom) Western blots of same fractions with an anti-apoB antibody are shown. D: Phospholipid levels of each fraction are shown.
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that the Apoe2/2·Apobec/ mice have twice as much TG-rich
VLDL as compared with the Apoe2/2 mice whose plasma
VLDL are more enriched with CE.
LpL assay
We examined whether the increased steady state levels
of VLDL-TG in the Apoe2/2·Apobec/ mice was caused by a
reduced lipolysis of VLDL-TG by LpL as compared with
Apoe2/2 mice. Free fatty acid released from VLDL-TG by
LpL was 2.8 	 0.5 nmol FFA/min/U in the Apoe2/2·
Apobec/ mice (n  5) as compared with 4.5 	 0.8 nmol
FFA/ml/U in the Apoe2/2 mice (n  4, Fig. 5). This 62%
difference was significant (P  0.01). There is a significant
correlation between the VLDL-FFA release (Fig. 5) and
the PL percentage of VLDL particle mass (Fig. 4) (r 
0.69, P  0.04). This implies that the VLDL with a lower
percentage of PL release less FFA under our assay condi-
tions. We also find that the mass percentage of PL per
VLDL particle is lowest in the Apoe 2/2·Apobec/ mice
(P  0.0001). This difference in individual VLDL-PL is
probably a result of the increased VLDL-TG and not a
cause of the decreased LpL lipolysis. Taken together with
the fact that the TG secretion rates in the two groups of
mice are the same, a significant part of the increase in
steady state levels of plasma VLDL-TG in the Apoe2/2·
Apobec/ mice results from a reduction in lipolysis of
VLDL-TG.
DISCUSSION
Apoe2/2 mice expressing human apoE-2 isoform in place
of mouse apoE exhibit exaggerated THL compared with
the majority of humans homozygous for APOE*2 who
have relatively low plasma cholesterol levels. The predom-
inant apoB containing lipoprotein accumulating in the
Apoe2/2 mice contains apoB-48 (5). In this paper, we exam-
ined whether or not this exaggerated THL phenotype is
because mice produce apoB-48 containing VLDL particles
from the liver. This is in contrast to human liver VLDL
that are entirely apoB-100 containing lipoproteins. We hy-
pothesized that if the Apoe2/2 mice had only apoB-100 con-
taining lipoprotein particles, their hyperlipoproteinemic
phenotype would be improved due to increased clearance
of the human-like VLDL remnants. Various other studies
support this hypothesis. For example, apoB-48-containing
particles are the primary circulating apoB-containing lipo-
protein in apoE deficient mice (19). Changing the apoB
in Apoe/ mice to totally apoB-100 by crossing them to
Apobec/ mice or with apoB-100 only mice have shown to
decrease their total plasma cholesterol by about 55% (20)
or 20% (21), respectively. These decreases were in both
VLDL-C and LDL-C, and resulted from increased clear-
ance of lipoprotein particles most likely via the apoB-100
binding to LDLR (20, 21). Thus, it can be argued that the
plasma lipid profile in the Apoe2/2·Apobec/ mice should
improve. However, the overall THL phenotype did not im-
prove in the Apoe2/2·Apobec/ mice when they produced
only apoB-100-containing VLDL and chylomicrons.
The exclusive presence of apoB-100 on lipoprotein par-
ticles in the Apoe2/2·Apobec/ mice did alter the metabo-
lism of the lipoprotein particles. Similar to the majority of
human APOE*2 homozygotes without THL, female Apoe2/2·
Apobec/ mice had a small but significant reduction in
IDL/LDL. The reduction in males was however not signif-
icant. It should be noted there is a sex predilection for low
LDL in female APOE*2 homozygotes that also have famil-
ial hypercholesterolemia (22). In the Apoe2/2·Apobec/
mice, there are two possible explanations for the reduc-
tion of cholesterol in the IDL/LDL range particles. It
could directly result from increased clearance of apoB-100
lipoproteins through binding of apoB-100 to the LDLR.
Furthermore, LDL clearance may be enhanced by the
poor competition of apoE-2-containing remnants with
apoB-100 containing LDL for the LDLR (23) or by the up
regulation of the LDLR in THL (24). Alternatively, the re-
duced IDL/LDL-C could be from decreased conversion of
VLDL particles to IDL/LDL particles. ApoB-100 associ-
ated with VLDL is not in a conformation that binds well to
the LDLR. For apoB-100 to become an effective ligand,
conversion of VLDL to IDL/LDL mainly through lipolysis
is required to expose LDLR binding sites in apoB-100. Al-
though there were no significant increases in either
VLDL-C or apoE in the Apoe2/2·Apobec/ mice compared
with the Apoe2/2 mice, there was a 2-fold increase in TG-
rich apoB-100 VLDL. This suggests that there is decreased
conversion of VLDL to IDL/LDL and/or increased VLDL
secretion.
We found that the Apoe2/2·Apobec/ VLDL particles are
poorer substrates for LpL than the Apoe2/2 VLDL, showing
a reduced rate (62%) of free fatty acid release in vitro.
This appears to be a major reason for the TG increase be-
cause there is no difference in TG secretion rates between
Fig. 3. TG secretion rate in the Apoe2/2·Apobec/ and Apoe2/2
mice. Mice were injected intravenously with Triton WR-1339 at 0.7
mg/g body weight. Plasma TG was measured at time 0 (i.e., before
Tyloxapol injection), 30 min (i.e., after tyloxapol injection), 60
min, 120 min, and 180 min and normalized for plasma volume and
liver weight. Micromoles of TG secreted per h per g liver weight
were calculated using the slope of the linear curve fit lines.
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the Apoe2/2·Apobec/ and Apoe2/2 mice. Increases in apoE
plasma levels can have a dose dependent inhibition on
LpL activity (25–28). However, we found the Apoe2/2·
Apobec/ mice have similar amounts of plasma and VLDL
apoE-2 as compared with the Apoe2/2 mice, which excludes
the levels of apoE-2 as a cause for decrease in VLDL lipoly-
sis. We note, however, that a possibility remains that the
reduced clearance of VLDL through receptor-mediated
pathways and/or HSPG-mediated endocytosis could also
be contributing to the increased VLDL and VLDL TG in
the Apoe2/2·Apobec/ mice. To further characterize the ca-
tabolism of TG in vivo, the response of Apoe2/2·Apobec/
and Apoe2/2 mice to oral fat challenge was performed and
revealed no difference between the mice (data not
shown). This was a surprise, but may be partly explained
by the recent finding that the Apobec1/ mice have re-
duced fat absorption as compared with wild-type mice
(29).
Similar degrees of increase in VLDL-TG have been seen
in other animal models where apoB-100 was exclusively
present on lipoproteins, although their mechanism has
not been explored. These models include Apoe/
Apobec/ mice (20), LDLR/ Apobec/ mice (20), and
apoB-100 only mice with or without a functional apoE
(21). Thus, our results of apoB-100 containing lipopro-
teins not being as efficient a substrate for LpL as com-
pared with apoB-48 lipoproteins can also explain the in-
creased VLDL-TG in these other apoB-100 exclusive mice.
In fact, absence of apoE and decreased VLDL conversion
are likely the reason for the accumulation of the less
atherogenic large VLDL in the Apoe/ apoB-100 only
mice verses the more atherogenic small LDL that accumu-
late in the LDLR/ apoB-100 only mice (30, 31). The de-
creased lipolysis could be due to a decreased efficiency of
interaction of apoB-100 VLDL with LpL as compared with
apoB-48 VLDL. These findings suggest a possibility that
apoB-100-containing particles are more resistant to lipoly-
sis by LpL, possibly due to the presence of the C-termi-
nal half of the apoB-100 protein that is missing in apoB-
48. If true, lipoproteins containing truncated apoB could
be used to “map” this LpL inhibition segment in apoB-
100. For example, an increase in apoB lipoprotein clear-
ance was first seen in humans with truncated apoB protein
(apoB-75 and apoB-89) containing lipoproteins (32–35).
Furthermore, mice producing apoB-70 (36) or apoB-81
(37) in place of apoB-100 have below normal TG levels. In
mice with truncated apoB-81 and apoB-83, a decrease in
production of apoB lipoproteins and an increase in trun-
cated apoB lipoprotein clearance have been reported (38,
39). This increased clearance of the truncated apoB lipo-
proteins is due to a loss of the C-terminus of apoB, which
possibly inhibits VLDL binding to the LDLR (40). VLDL
lipolysis in these apoB-truncated mice has not been mea-
sured. In vitro assays have shown that apoE inhibits LpL
and some of this inhibition is associated with the LDLR
binding region of apoE (41). This region is highly homol-
ogous to the LDLR binding site B of apoB-100 (40).
Therefore, site B and other C-terminal areas may be re-
Fig. 4. Compositional analysis of VLDL from
Apoe2/2·Apobec/ and Apoe2/2 mice. Percentage of
cholesterol ester (CE), free cholesterol (FC), pro-
tein (Pro), phospholipid (PL), and TG in total lipo-
protein particle mass are shown.
Fig. 5. In vitro lipolysis of VLDL-TG from Apoe2/2 and Apoe2/2·
Apobec/ female mice. The data was curve fitted and the nmoles of
free fatty acids released from 8.0 g of VLDL TG is shown.
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sponsible for the inhibitory activity of apoB-100 on LpL
hydrolysis of VLDL.
In summary, we have shown that the presence of an ad-
ditional LDLR binding site on apoB containing lipopro-
teins does not improve the type-III hyperlipoproteinemia
seen in Apoe2/2 mice. The Apoe2/2·Apobec/ mice had
slightly improved LDL-C levels but much worsened plasma
VLDL-TG levels. These changes result from the Apoe2/2·
Apobec/ apoB-100 VLDL being a less suitable substrate
for LpL as compared with the predominately apoB-48
VLDL in Apoe2/2 mice. We speculate that the C-terminus of
apoB-100 has an additional and important role in control-
ling the interaction of apoB lipoproteins with LpL just as
it does in apoB-100 interactions with the LDLR (40, 42).
This difference in LpL catabolism may explain the com-
mon observation that chylomicrons (apoB-48 lipopro-
teins) can out-compete VLDL (apoB-100 lipoproteins) for
conversion to remnant lipoproteins (43). Why the major-
ity of human APOE*2 homozygotes with defective apoE-2
have better than normal plasma lipid and lipoprotein pro-
files remains to be explained.
The authors thank Dr. John Parks (Wake Forest University
School of Medicine, Deptartment of Pathology, Winston-Salem,
NC) for helpful comments on this manuscript, and Ben Rob-
erts for excellent technical assistance. We also thank Dr. Pierre
Neuenschwander (University of Texas Health Science Center
at Tyler, Biomedical Research) for help with the curve fitting of
the VLDL lipolysis assay data. This research was supported by
Grants RR00111 (M.E.H.), and HL42630 (N.M.) from the Na-
tional Institutes of Health.
REFERENCES
1. Utermann, G., M. Hees, and A. Steinmetz. 1977. Polymorphism of
apolipoprotein E and occurrence of dysbetalipoproteinaemia in
man. Nature. 269: 604–607.
2. Mahley, R. W., and S. C. Rall, Jr. 1995. Type III hyperlipoproteine-
mia (Dysbetalipoproteinemia): The Role of Apolipoprotein E in
Normal and Abnormal Metabolism. In The Molecular and Meta-
bolic Bases of Inherited Disease. 7th edition. Volume 2. C. R.
Scriver, A. L. Beaudet, W. S. Sly, and D. Valle. McGraw-Hill, Inc.,
New York, New York. 1953–1980.
3. Mahley, R. W., Y. Huang, and S. C. Rall, Jr. 1999. Pathogenesis of
type III hyperlipoproteinemia (dysbetalipoproteinemia). Ques-
tions, quandaries, and paradoxes. J. Lipid Res. 40: 1933–1949.
4. Davignon, J., J. S. Cohn, L. Mabile, and L. Bernier. 1999. Apolipo-
protein E and atherosclerosis: insight from animal and human
studies. Clin. Chim. Acta. 286: 115–143.
5. Sullivan, P. M., H. Mezdour, S. H. Quarfordt, and N. Maeda. 1998.
Type III hyperlipoproteinemia and spontaneous atherosclerosis in
mice resulting from gene replacement of mouse Apoe with human
Apoe*2. J. Clin. Invest. 102: 130–135.
6. Knouff, C., M. E. Hinsdale, H. Mezdour, M. K. Altenburg, M. Wa-
tanabe, S. H. Quarfordt, P. M. Sullivan, and N. Maeda. 1999. Apo E
structure determines VLDL clearance and atherosclerosis risk in
mice. J. Clin. Invest. 103: 1579–1586.
7. Knouff, C., S. Malloy, J. Wilder, M.K. Altenburg, and N. Maeda.
2000. Doubling expression of the LDL receptor by truncation of
the 3 UTR sequence ameliorates type III hyperlipoproteinemia in
mice expressing the Human ApoE2 isoform. J. Biol. Chem. 276:
3856–3862
8. Powell, L. M., S. C. Wallis, R. J. Pease, Y. H. Edwards, T. J. Knott,
and J. Scott. 1987. A novel form of tissue-specific RNA processing
produces apolipoprotein- B48 in intestine. Cell. 50: 831–840.
9. Chen, S. H., G. Habib, C. Y. Yang, Z. W. Gu, B. R. Lee, S. A. Weng,
S. R. Silberman, S. J. Cai, J. P. Deslypere, M. Rosseneu, A. M. Gotto
Jr., W. H. Li, and L. Chan. 1987. Apolipoprotein B-48 is the prod-
uct of a messenger RNA with an organ-specific in-frame stop
codon. Science. 238: 363–366.
10. Oka, K., K. Kobayashi, M. Sullivan, J. Martinez, B. B. Teng, K. Ishi-
mura-Oka, and L. Chan. 1997. Tissue-specific inhibition of apolipo-
protein B mRNA editing in the liver by adenovirus-mediated trans-
fer of a dominant negative mutant APOBEC-1 leads to increased
low density lipoprotein in mice. J. Biol. Chem. 272: 1456–1460.
11. Higuchi, K., K. Kitagawa, K. Kogishi, and T. Takeda. 1992. Devel-
opmental and age-related changes in apolipoprotein B mRNA ed-
iting in mice. J. Lipid Res. 33: 1753–1764.
12. Morrison, J. R., C. Paszty, M. E. Stevens, S. D. Hughes, T. Forte, J.
Scott, and E. M. Rubin. 1996. Apolipoprotein B RNA editing en-
zyme-deficient mice are viable despite alterations in lipoprotein
metabolism. Proc. Natl. Acad. Sci. USA. 93: 7154–7159.
13. Warnick, G. R., J. Benderson, and J. J. Albers. 1982. Dextran sul-
fate-Mg2 precipitation procedure for quantitation of high- den-
sity-lipoprotein cholesterol. Clin. Chem. 28: 1379–1388.
14. Sullivan, P. M., H. Mezdour, Y. Aratani, C. Knouff, J. Najib, R. L.
Reddick, S. H. Quarfordt, and N. Maeda. 1997. Targeted replace-
ment of the mouse apolipoprotein E gene with the common hu-
man APOE3 allele enhances diet-induced hypercholesterolemia
and atherosclerosis. J. Biol. Chem. 272: 17972–17980.
15. van Dijk, K. W., B. J. van Vlijmen, H. B. van’t Hof, A. van der Zee,
S. Santamarina-Fojo, T. J. van Berkel, L. M. Havekes, and M. H.
Hofker. 1999. In LDL receptor-deficient mice, catabolism of rem-
nant lipoproteins requires a high level of apoE but is inhibited by
excess apoE. J. Lipid Res. 40: 336–344.
16. Maugeais, C., U. J. Tietge, K. Tsukamoto, J. M. Glick, and D. J.
Rader. 2000. Hepatic apolipoprotein E expression promotes very
low density lipoprotein-apolipoprotein B production in vivo in
mice. J. Lipid Res. 41: 1673–1679.
17. Li, X., F. Catalina, S. M. Grundy, and S. Patel. 1996. Method to
measure apolipoprotein B-48 and B-100 secretion rates in an indi-
vidual mouse: evidence for a very rapid turnover of VLDL and
preferential removal of B-48- relative to B-100-containing lipopro-
teins. J. Lipid Res. 37: 210–220.
18. Wish L., J. Furth, and R. H. Storey. 1950. Direct determination of
plasma, cell, and organ-blood volumes in normal and hypervo-
lemic mice. Proc. Soc. Exp. Biol. Med. 74: 644–648.
19. Zhang, S. H., R. L. Reddick, J. A. Piedrahita, and N. Maeda. 1992.
Spontaneous hypercholesterolemia and arterial lesions in mice
lacking apolipoprotein E. Science. 258: 468–471.
20. Nakamuta, M., S. Taniguchi, B. Y. Ishida, K. Kobayashi, and L.
Chan. 1998. Phenotype interaction of apobec-1 and CETP, LDLR,
and apoE gene expression in mice: role of apoB mRNA editing in
lipoprotein phenotype expression. Arterioscler. Thromb. Vasc. Biol.
18: 747–755.
21. Farese, R. V., Jr., M. M. Veniant, C. M. Cham, L. M. Flynn, V.
Pierotti, J. F. Loring, M. Traber, S. Ruland, R. S. Stokowski, D.
Huszar, and S. G. Young. 1996. Phenotypic analysis of mice ex-
pressing exclusively apolipoprotein B48 or apolipoprotein B100.
Proc. Natl. Acad. Sci. USA. 93: 6393–6398.
22. Ferrieres, J., C. F. Sing, M. Roy, J. Davignon, and S. Lussier-Cacan.
1994. Apolipoprotein E polymorphism and heterozygous familial
hypercholesterolemia. Sex-specific effects. Arterioscler. Thromb. 14:
1553–1560.
23. Woollett, L. A., Y. Osono, J. Herz, and J. M. Dietschy. 1995. Apolipopro-
tein E competitively inhibits receptor-dependent low density lipopro-
tein uptake by the liver but has no effect on cholesterol absorption or
synthesis in the mouse. Proc. Natl. Acad. Sci. USA. 92: 12500–12504.
24. Davignon, J., R. E. Gregg, and C. F. Sing. 1988. Apolipoprotein E
polymorphism and atherosclerosis. Arteriosclerosis. 8: 1–21.
25. Jong, M. C., V. E. Dahlmans, M. H. Hofker, and L. M. Havekes.
1997. Nascent very-low-density lipoprotein triacylglycerol hydroly-
sis by lipoprotein lipase is inhibited by apolipoprotein E in a dose-
dependent manner. Biochem. J. 328: 745–750.
26. Huang, Y., X. Q. Liu, S. C. Rall, Jr., and R. W. Mahley. 1998. Apoli-
poprotein E2 reduces the low density lipoprotein level in trans-
genic mice by impairing lipoprotein lipase-mediated lipolysis of
triglyceride-rich lipoproteins. J. Biol. Chem. 273: 17483–17490.
27. Huang, Y., X. Q. Liu, S. C. Rall, Jr., J. M. Taylor, A. von Eckardstein,
G. Assmann, and R. W. Mahley. 1998. Overexpression and accumu-
lation of apolipoprotein E as a cause of hypertriglyceridemia. J.
Biol. Chem. 273: 26388–26393.
1528 Journal of Lipid Research Volume 43, 2002
28. Huang, Y., Z. S. Ji, W. J. Brecht, S. C. Rall, Jr., J. M. Taylor, and R. W.
Mahley. 1999. Overexpression of apolipoprotein E3 in transgenic
rabbits causes combined hyperlipidemia by stimulating hepatic
VLDL production and impairing VLDL lipolysis. Arterioscler.
Thromb. Vasc. Biol. 19: 2952–2959.
29. Kendrick, J. S., L. Chan, and J. A. Higgins. 2001. Superior role of
apolipoprotein B48 over apolipoprotein B100 in chylomicron as-
sembly and fat absorption: an investigation of apobec-1 knock-out
and wild-type mice. Biochem. J. 356: 821–827.
30. Veniant, M. M., S. Withycombe, and S. G. Young. 2001. Lipopro-
tein size and atherosclerosis susceptibility in Apoe(/) and
Ldlr(/) mice. Arterioscler. Thromb. Vasc. Biol. 21: 1567–1570.
31. Veniant, M. M., M. A. Sullivan, S. K. Kim, P. Ambroziak, A. Chu, M. D.
Wilson, M. K. Hellerstein, L. L. Rudel, R. L. Walzem, and S. G.
Young. 2000. Defining the atherogenicity of large and small lipo-
proteins containing apolipoprotein B100. J. Clin. Invest. 106:
1501–1510.
32. Krul, E. S., M. Kinoshita, P. Talmud, S. E. Humphries, S. Turner, A. C.
Goldberg, K. Cook, E. Boerwinkle, and G. Schonfeld. 1989. Two
distinct truncated apolipoprotein B species in a kindred with hy-
pobetalipoproteinemia. Arteriosclerosis. 9: 856–868.
33. Parhofer, K. G., P. H. Barrett, D. M. Bier, and G. Schonfeld. 1992.
Lipoproteins containing the truncated apolipoprotein, Apo B-89,
are cleared from human plasma more rapidly than Apo B-100-
containing lipoproteins in vivo. J. Clin. Invest. 89: 1931–1937.
34. Parhofer, K. G., A. Daugherty, M. Kinoshita, and G. Schonfeld.
1990. Enhanced clearance from plasma of low density lipoproteins
containing a truncated apolipoprotein, apoB-89. J. Lipid Res. 31:
2001–2007.
35. Krul, E. S., K. G. Parhofer, P. H. Barrett, R. D. Wagner, and G.
Schonfeld. 1992. ApoB-75, a truncation of apolipoprotein B associ-
ated with familial hypobetalipoproteinemia: genetic and kinetic
studies. J. Lipid Res. 33: 1037–1050.
36. Homanics, G. E., T. J. Smith, S. H. Zhang, D. Lee, S. G. Young, and
N. Maeda. 1993. Targeted modification of the apolipoprotein B
gene results in hypobetalipoproteinemia and developmental ab-
normalities in mice. Proc. Natl. Acad. Sci. USA. 90: 2389–2393.
37. Toth, L. R., T. J. Smith, C. Jones, H. V. de Silva, O. Smithies, and N.
Maeda. 1996. Two distinct apolipoprotein B alleles in mice gener-
ated by a single ‘in- out’ targeting. Gene. 178: 161–168.
38. Kim, E., C. M. Cham, M. M. Veniant, P. Ambroziak, and S. G.
Young. 1998. Dual mechanisms for the low plasma levels of trun-
cated apolipoprotein B proteins in familial hypobetalipoprotein-
emia. Analysis of a new mouse model with a nonsense mutation in
the Apob gene. J. Clin. Invest. 101: 1468–1477.
39. Srivastava, R. A., L. Toth, N. Srivastava, M. E. Hinsdale, N. Maeda,
A. B. Cefalu, M. Averna, and G. Schonfeld. 1999. Regulation of
the apolipoprotein B in heterozygous hypobetalipoproteinemic
knock-out mice expressing truncated apoB, B81. Low production
and enhanced clearance of apoB cause low levels of apoB. Mol.
Cell. Biochem. 202: 37–46.
40. Boren, J., I. Lee, W. Zhu, K. Arnold, S. Taylor, and T. L. Innerarity.
1998. Identification of the low density lipoprotein receptor-binding
site in apolipoprotein B100 and the modulation of its binding ac-
tivity by the carboxyl terminus in familial defective apo-B100. J.
Clin. Invest. 101: 1084–1093.
41. McConathy, W. J., and C. S. Wang. 1989. Inhibition of lipoprotein
lipase by the receptor-binding domain of apolipoprotein E. FEBS
Lett. 251: 250–252.
42. Boren, J., U. Ekstrom, B. Agren, P. Nilsson-Ehle, and T. L. Innerar-
ity. 2001. The molecular mechanism for the genetic disorder fa-
milial defective apolipoprotein B100. J. Biol. Chem. 276: 9214–
9218.
43. Chappell, D. A., and J. D. Medh. 1998. Receptor-mediated mecha-
nisms of lipoprotein remnant catabolism. Prog. Lipid Res. 37: 393–
422.
